Thirty cancer patients suffering from psychological distress participated in a pilot project of individual psychotherapy that offered – over a four week period of time – approximately twelve hours of conventional verbal interaction and a single intensive drug-assisted therapy session that employed dipropyltryptamine (DPT), a short-acting psychedelic drug. The efficacy of the total therapeutic approach in enhancing the quality of life is indicated by the analysis of data from psychological tests and independent ratings completed before and after the treatment intervention. The relative merits of DPT in comparison with LSD and the need to pursue a controlled study are discussed.
Get full access to this article
View all access options for this article.
References
1.
PahnkeW. N.KurlandA. A.GoodmanL. E., and RichardsW. A., LSD-Assisted Psychotherapy with Terminal Cancer Patients, HicksR. E. and FinkP. J. (eds.), Psychedelic Drugs, Grune and Stratton, New York, pp. 33–42, 1969.
2.
PahnkeW. N.KurlandA. A.UngerS.SavageC.WolfS., and GoodmanL. E., Psychedelic Therapy (Utilizing LSD) with Terminal Cancer Patients, Journal of Psychedelic Drugs, 3, pp. 63–75, 1970.
3.
RichardsW. A.GrofS.GoodmanL. E., and KurlandA. A., LSD-Assisted Psychotherapy and the Human Encounter with Death, Journal of Transpersonal Psychology, 4, pp. 121–150, 1972.
4.
KurlandA. A.GrofS.PahnkeW. N., and GoodmanL. E., Psychedelic Drug-Assisted Psychotherapy in Patients with Terminal Cancer, GoldbergI. K.MalitzS. and KutscherA. H. (eds.), Psychopharmacological Agents for the Terminally Ill and Bereaved, Foundation of Thanatology (Columbia University Press, distributor), New York, pp. 86–133, 1973.
5.
RichardsW. A., Counseling, Peak Experiences and the Human Encounter with Death, Ph.D. dissertation, The Catholic University of America, Washington, D. C., 1975; Xerox University Microfilms, Ann Arbor, No. 75–18, p. 531.
6.
SzaraS., The Comparison of the Psychotic Effects of Tryptamine Derivatives with Effects of Mescaline and LSD-25 in Self-Experiments, Garattini and Ghetti (eds.), Psychotropic Drugs, Elsevier, Amsterdam, pp. 460–467, 1957.
7.
SzaraS., Hallucinogenic Effects and Metabolism of Tryptamine Derivatives in Man, Federation Proceedings, 20, pp. 885–888, 1961.
8.
VourlekisA.FaillaceL. A., and SzaraS., Psychotherapy Combined with Psychodysleptic Tryptamine Derivatives and an Active Placebo, Neuro-Psycho-Pharmacology: Proceedings of the Fifth International Congress of the Collegium Internationale Neuro-Psycho-Pharmacologicum, Excerpta Medica Foundation (International Congress Series No. 129), New York, pp. 1116–1118, 1967.
9.
SzaraS.RocklandL. H.RosenthalD., and HandlonJ. H., Psychological Effects and Metabolism of N,N-diethyltryptamine in Man, Archives of General Psychiatry, 15, pp. 320–329, 1966.
10.
FaillaceL. A.VourlekisA., and SzaraS., Clinical Evaluation of Some Hallucinogenic Tryptamine Derivatives, Journal of Nervous and Mental Disease, 145, pp. 306–313, 1967.
11.
SoskinR.A.GrofS., and RichardsW.A., Low Doses of Dipropyltryptamine in Psychotherapy, Archives of General Psychiatry, 28, pp. 817–821, 1973.
12.
GrofS.SoskinR. A.RichardsW. A., and KurlandA. A., DPT as an Adjunct in Psychotherapy of Alcoholics, International Journal of Pharmacopsychiatry, 8, pp. 129–144, 1973.
13.
WeismanA. D., A Psychiatrists' View: Death and Responsibility, Psychiatric Opinion, 3, pp. 22–26, 1966.
14.
KincannonJ. C., Prediction of the Standard MMPI Scale Scores from 71 Items, Journal of Consulting and Clinical Psychology, 32, pp. 319–325, 1968.
15.
ShostromE. L., A Test for the Measurement of Self-Actualization, Educational and Psychological Measurement, 24, pp. 207–218, 1965.
16.
SavageC. and StolaroffM. J., Clarifying the Confusion Regarding LSD-25, Journal of Nervous and Mental Disease, 140, pp. 218–221, 1965.
17.
BonnyH. and PahnkeW. N., The Use of Music in Psychedelic (LSD) Therapy, Journal of Music Therapy, 9, pp. 64–87, 1972.
18.
Kübler-RossE., On Death and Dying, Macmillan, New York, 1969.
19.
SaundersC., Care of the Dying, Macmillan, London, 1959.
20.
HintonJ., Dying, Penguin Books, Middlesex, 1967.
21.
WeismanA. D., On Dying and Denying: A Psychiatric Study of Terminality, Behavioral Publications, New York, 1972.
22.
PahnkeW. N. and RichardsW. A., Implications of LSD and Experimental Mysticism, Journal of Religion and Health, 5, pp. 175–208, 1966.
23.
JamesW., The Varieties of Religious Experience, Modern Library, New York, 1902.
24.
KastE., LSD and the Dying Patient, Chicago Medical School Quarterly, 26, pp. 80–87, 1966.
25.
NaranjoC., The Healing Journey, Pantheon, New York, 1973.
26.
KhorramzadehE. and LotfyA. O., The Use of Ketamine in Psychiatry, Psychosomatics, 14, pp. 344–346, 1973.
27.
DiMascioA. and KlermanG., Experimental Human Psychopharmacology: The Role of Non-Drug Factors, Sarwer-FonerG. J. (ed.), The Dynamics of Psychiatric Drug Therapy, Charles C. Thomas, Springfield, pp. 56–90, 1960.
